Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pediatric Protocol In Written Agreement Should Be Strictly Followed - FDA

This article was originally published in The Tan Sheet

Executive Summary

NDA sponsors will be expected to adhere precisely to study protocols included in written agreements, FDA's revised guidance on pediatric exclusivity states.

You may also be interested in...

Pediatric study proposals will be prioritized by time of submission, FDA guidance states.

PEDIATRIC DRUG STUDY PROPOSALS WILL BE PRIORITIZED BY TIME OF SUBMISSION and the date of expiry of marketing exclusivity or patent, FDA's June 29 "Qualifying for Pediatric Exclusivity" guidance states. The agency will give top priority review to drugs that lose marketing exclusivity on or before March 31, 1999 if the sponsor submits a proposed pediatric study request by this Aug. 31. The drug must be one of about 490 included in the priority pediatric drug list issued May 20, of which 23 are OTCs ("The Tan Sheet" May 25, p. 12).

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts